Acute Lymphoblastic Leukemia in Children | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …

Purpose To review the impact of collaborative studies on advances in the biology and
treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. Methods A …

Structural chromosome rearrangements may result in the exchange of coding or regulatory
DNA sequences between genes. Many such gene fusions are strong driver mutations in …

Acute lymphoblastic leukemia (ALL) is the commonest childhood tumor and remains a
leading cause of cancer death in the young. In the last decade, microarray and sequencing …

Significant advances have been made in the last decade toward a better understanding of
the disease pathogenesis and the development of novel therapies that target specific …

Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer and an important
cause of morbidity from haematological malignancies in adults. In the past several years, we …

TCF3-HLF− positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an
integrated approach, we uncovered distinct mutation, gene expression and drug response …

Major progress has been recently made in understanding the molecular pathogenesis of
myeloproliferative neoplasms (MPN). Mutations in one of four genes—JAK2, MPL, CALR …

Background Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with
CRLF2 and/or JAK pathway mutations. Procedure A phase 1 trial of ruxolitinib was …

Adoptive transfer of T cells genetically modified to express chimeric antigen receptors
(CARs) targeting the CD19 B cell–associated protein have demonstrated potent activity …